Nuwellis (NUWE) Equity Ratio (2011 - 2026)
Nuwellis posted quarterly Equity Ratio of 0.38 for Q1 2026, down 25.15% year-on-year from 0.51 in Q1 2025, and down 10.87% on a QoQ basis from 0.43 in Q4 2025.
Nuwellis (NUWE) has 16 years of Equity Ratio data on file, last reported at 0.38 in Q1 2026.
- For the quarter ending Q1 2026, Equity Ratio fell 25.15% year-over-year to 0.38; the trailing twelve-month figure through Mar 2026 stood at 0.38 (down 25.15% YoY), and the FY2025 full-year result was 0.43, down 35.19% from the prior year.
- Equity Ratio for Q1 2026 stood at 0.38, down from 0.43 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.83 in Q1 2022 and bottomed at 1.1 in Q2 2024.
- The 5-year median for Equity Ratio is 0.5 (2022), against an average of 0.37.
- The widest annual swing landed in 2024, when Equity Ratio plunged 255.13%; it then surged 284.44% in 2025.
- A 5-year view of Equity Ratio shows it stood at 0.5 in 2022, then slumped by 38.89% to 0.31 in 2023, then jumped by 116.25% to 0.66 in 2024, then tumbled by 35.19% to 0.43 in 2025, then slipped by 10.87% to 0.38 in 2026.
- The last three Equity Ratio figures came in at 0.38 (Q1 2026), 0.43 (Q4 2025), and 0.49 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 0.47 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 0.50 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 0.54 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 0.59 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 0.78 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 0.45 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 0.29 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 0.67 |
| 10 | Nuwellis | 1.45 Mn | -630,292.49 | 1.68 Mn | 0.38 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.38 |
| Dec 31, 2025 | 0.43 |
| Sep 30, 2025 | 0.49 |
| Jun 30, 2025 | -0.97 |
| Mar 31, 2025 | 0.51 |
| Dec 31, 2024 | 0.66 |
| Sep 30, 2024 | 0.47 |
| Jun 30, 2024 | -1.10 |
| Mar 31, 2024 | 0.13 |
| Dec 31, 2023 | 0.31 |
| Sep 30, 2023 | 0.69 |
| Jun 30, 2023 | 0.71 |
| Mar 31, 2023 | 0.74 |
| Dec 31, 2022 | 0.50 |
| Sep 30, 2022 | 0.76 |
| Jun 30, 2022 | 0.80 |
| Mar 31, 2022 | 0.83 |
| Dec 31, 2021 | 0.85 |
| Sep 30, 2021 | 0.88 |
| Jun 30, 2021 | 0.88 |
| Mar 31, 2021 | 0.90 |
| Dec 31, 2020 | 0.82 |
| Sep 30, 2020 | 0.86 |
| Jun 30, 2020 | 0.73 |
| Mar 31, 2020 | 0.77 |
| Dec 31, 2019 | 0.36 |
| Sep 30, 2019 | 0.57 |
| Jun 30, 2019 | 0.74 |
| Mar 31, 2019 | 0.82 |
| Dec 31, 2018 | 0.68 |
| Sep 30, 2018 | 0.82 |
| Jun 30, 2018 | 0.81 |
| Mar 31, 2018 | 0.86 |
| Dec 31, 2017 | 0.88 |
| Sep 30, 2017 | 0.75 |
| Jun 30, 2017 | 0.81 |
| Mar 31, 2017 | 0.49 |
| Dec 31, 2016 | 0.24 |
| Sep 30, 2016 | 0.37 |
| Jun 30, 2016 | 0.28 |
| Mar 31, 2016 | 0.43 |
| Dec 31, 2015 | 0.50 |
| Sep 30, 2015 | 0.63 |
| Jun 30, 2015 | 0.70 |
| Mar 31, 2015 | 0.78 |
| Dec 31, 2014 | 0.90 |
| Sep 30, 2014 | 0.93 |
| Jun 30, 2014 | 0.93 |
| Mar 31, 2014 | 0.95 |
| Dec 31, 2013 | 0.94 |
| Sep 30, 2013 | 0.95 |
| Jun 30, 2013 | 0.90 |
| Mar 31, 2013 | 0.83 |
| Dec 31, 2012 | 0.86 |
| Sep 30, 2012 | 0.88 |
| Jun 30, 2012 | 0.22 |
| Mar 31, 2012 | 0.59 |
| Dec 31, 2011 | 0.62 |